Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor.
Selin KucukyurtYeliz Yagiz OzogulAbdülkadir ErçalışkanLevent KabasakalAhmet Emre EskazanPublished in: Cancer reports (Hoboken, N.J.) (2020)
The physicians should be aware of the short- and long-term hematologic toxicities of PRRT including TR-CML, and careful monitoring is mandatory in this group of patients.